- Investing.com
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Pipeline Promise | Merus N.V.'s innovative antibody therapies for cancer treatment show potential, with lead candidates petosemtamab and zenocutuzumab demonstrating promising clinical results |
Financial Outlook | Analysts project revenue growth to $525.9M by 2027, with EPS turning positive. Current price targets range from $67 to $109, reflecting bullish sentiment |
Market Positioning | Explore Merus's unique position in oncology drug development, leveraging its proprietary Biclonics® technology to potentially capture a significant market share |
Growth Catalysts | Delve into Merus's future prospects, including potential accelerated approvals, strategic partnerships, and pipeline expansion opportunities in the competitive oncology landscape |
Metrics to compare | MRUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −12.6x | −1.4x | −0.5x | |
PEG Ratio | 0.14 | 0.00 | 0.00 | |
Price/Book | 5.8x | 2.7x | 2.6x | |
Price / LTM Sales | 86.1x | 8.3x | 3.3x | |
Upside (Analyst Target) | 43.8% | 179.7% | 43.5% | |
Fair Value Upside | Unlock | 6.9% | 6.8% | Unlock |